kennedy merck - Search News

Reuters on MSN · 3d

Kennedy would keep legal fees from Merck cases if confirmed

Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President Donald Trump's secretary of the U.S. Department of Health and Human Services,

The New York Times · 4d

Kennedy Would Keep Stake in HPV Vaccine Suit if Confirmed

Robert F. Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, Merck, if confirmed.

Business Insider · 3d

Kennedy Jr. to keep vaccine suit stake if confirmed as health chief, FT says

Robert Kennedy Jr. will keep his share of any windfall from litigation against Merck (MRK) even if he becomes Donald Trump’s top U.S. health

The Financial Times · 4d

Robert Kennedy vows to keep vaccine suit share if confirmed as Trump health chief

Robert F Kennedy Jr says he is entitled to keep interests in cases that do not involve the US or in which the state does not have a ‘direct and substantial interest’ © AP Robert Kennedy vows to keep v

8d

Exclusive-Kennedy Played Key Role in Vaccine Case Against Merck

(Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its ...

3don MSN

RFK Jr. says he’ll keep making money on anti-vaccine lawsuits while in office

The secretary of Health and Human Services nominee wrote in an ethics agreement that he would keep receiving contingency fees ...

4don MSN

RFK Jr. intends to keep financial interest in some lawsuits brought by firm that challenges pharmaceutical companies

Robert F. Kennedy, Jr. – the vaccine skeptic President Donald Trump has nominated to serve as Health and Human Services ...

Kennedy's Controversial Nomination: A Legal Fees Debate in the Health Sector

Robert F. Kennedy Jr.'s nomination as Secretary of Health and Human Services has sparked debate due to his previously earned ...

2d

Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results